Marinomed Biotech AG (WBO:MARI) Total Equity: €-7.05 Mil (As of Dec. 2025)


WBO:MARI Marinomed Biotech AG WBO:MARI
42 GF Score
Price €9.60
GF Value €18.59
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Marinomed Biotech AG Total Equity?

Marinomed Biotech AG WBO:MARI -3.52% 42 Total Equity is €-7.05 Mil as of Dec. 2025. GuruFocus rates WBO:MARI with a GF Score™ of 42/100 and a GF Value™ of €18.59 (Possible Value Trap). The stock has 7 warning signs investors should review.

Marinomed Biotech AG's total equity for the quarter that ended in Dec. 2025 was €-7.05 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Marinomed Biotech AG Total Equity Historical Data

* Premium members only.

The historical data trend for Marinomed Biotech AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marinomed Biotech AG Total Equity Chart

Marinomed Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 -4.16 -12.60 -26.16 -7.05

Marinomed Biotech AG Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.60 -20.55 -26.16 -5.44 -7.05
WBO:MARI
42GF Score
Marinomed Biotech AG WBO:MARI
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marinomed Biotech AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Marinomed Biotech AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5.951-12.996
=-7.05

Marinomed Biotech AG's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5.951-12.996
=-7.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €-7.05 Mil mean?
Marinomed Biotech AG (WBO:MARI) has a Total Equity of €-7.05 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Marinomed Biotech AG and its competitors.
Is Marinomed Biotech AG's Total Equity too high?
Marinomed Biotech AG's current Total Equity is €-7.05 Mil. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Total Equity compare to VRTX and REGN?
Marinomed Biotech AG's Total Equity of €-7.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Marinomed Biotech AG and its competitors. Marinomed Biotech AG's current Total Equity is €-7.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.59, compared to a current price of €9.60 — trading 48.4% below its estimated fair value. The current Total Equity is €-7.05 Mil. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Total Equity is €-7.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €9.60 is trading 48.4% below its estimated GF Value™ of €18.59. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for WBO:MARI:

  • Total Equity: €-7.05 Mil
  • GF Value™: €18.59 vs. price of €9.60 (48.4% below fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Marinomed Biotech AG Business Description

Other Exchanges 93Z:Germany
Address Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score

Get the complete analysis for WBO:MARI

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.60
Price
€18.59
GF Value